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Letter to the Editor
Am. J. Hum. Genet. 78:1092, 2006
Response from Maraganore et al.
To the Editor:
In this issue, four independent research teams present
new genetic association data for 13 SNPs previously re-
ported by us to be potentially associated with Parkinson
disease (PD [MIM 168600]).1 Two groups2,3 report sta-
tistically significant association between one or more of
these SNPs and PD, whereas two groups4,5 find no sta-
tistically significant association between PD and any of
the SNPs investigated. In an accompanying letter,6 Dr.
Richard H. Myers provides his qualitative assessment of
the implications of these new results.
We have performed a Mantel-Haenszel analysis, using
10 of the 13 SNPs not displaying linkage disequilibrium
(LD) with each other—combining the data of Li et al.,3
Farrer et al.,4 and Goris et al.5—to provide an overall
quantitative assessment of the new results. The odds ra-
tios (ORs) are reported for the SNP alleles that increase
the risk of PD1 (table 1). The X-linked SNP rs7878232
was not included in this analysis, since subgroup-level
data for males and females were not reported by all
groups. The results of Clarimon et al.2 were also not
included, given the significant difference in SNP allele
frequency observed between the European and Taiwa-
nese control samples. This analysis reveals that none of
the 10 SNPs shows statistically significant association
with PD (i.e., ). As pointed out in many of theP ! .05
accompanying letters, this failure to replicate may be
due, in part, to differences in sample ascertainment and
demographics.
A Mantel-Haenszel analysis combining these new re-
sults with those from tier 2 of Maraganore et al. reveal
five SNPs with and smaller effect sizes than wereP ! .05
originally reported1 (table 1). Although we are aware
that these low P values may, at least in part, be explained
by multiple testing, additional data are required to de-
termine if these SNPs truly confer PD susceptibility or
if they represent false-positive associations. Despite the
small ORs, the point estimates of attributable risk for
PD in the total data is still quite large for two of these
SNPs (rs10200894 population-attributable risk 0.27,
95% CI 0.04–0.77; rs7520966 population-attributable
risk 0.21, 95% CI 0.1–0.39). If these are true associa-
tions, they may have substantial practical impact on PD.
We do not agree with Dr. Myers6 that our failure to
identify an association between the LRRK2 gene and
PD in our original study is evidence of a false-negative
result. Farrer et al. have reported elsewhere that only a
very small number of the individuals with PD studied
in our original whole-genome scan have a mutation in
the LRRK2 (MIM 609007) gene.7
We also do not consider the positive association find-
ings between SNP rs7702187 and PD in a Taiwanese
population by Clarimon et al.2 to be a replication of our
original study results, since the SNP allele associated
with PD susceptibility is not the same in the two studies.
However, further work to follow up these results in the
Taiwanese population seems warranted.
It is gratifying that our hypotheses have been tested
rapidly by many groups. The Michael J. Fox Founda-
tion, which funded our original research, also has a
large-scale replication study under way. Given the low
heritability estimates for PD,8 our initial study may have
been underpowered for the detection of significant ge-
netic associations, in part, because of the large number
of genetic markers tested. Therefore, it may be prudent
not to limit replication of our study to the 13 SNPs that
we initially highlighted but to also consider additional
SNPs and genes that had suggestive findings (as in the
text files published in the online-only version of our orig-
inal article).1
DEMETRIUS M. MARAGANORE,1
MARIZA DE ANDRADE,2 TIMOTHY G. LESNICK,2
P. V. KRISHNA PANT,3 DAVID R. COX,3 AND
DENNIS G. BALLINGER3
Departments of 1Neurology and 2Health Sciences
Research, Mayo Clinic College of Medicine, Rochester,
MN; and 3Perlegen Sciences, Mountain View, CA
Web Resources
The URLs for data presented herein are as follows:
dbSNP, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMDpsearch
&DBpsnp
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.nlm
.nih.gov/Omim/ (for PD and LRRK2)
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